Biohaven Ltd.

The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven's experimental spinocerebellar ataxia treatment.

Biohaven Ltd. (NYSE:BHVN) stock is surging on Thursday with a session volume of 10.293 million versus an average volume of 2.585 million after an update on the spinocerebellar ataxia (SCA) program.

Biohaven Ltd. (NYSE:BHVN) entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phas

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation follow-on IgG degraders. Biohaven will receive up to $100 million in near-term payments, including $80 million upfront and eligible to receive another $20 million upon a milestone achievement anticipated within a year, and royalties of approximately twenty percent on net sales by Ono in the licensed territory.

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORT

Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development. First-in-class FGFR3 ADC: BHV-1530 is a first-in-class potential FGFR3-directed antibody-drug conjugate incorporating Biohaven's proprietary TopoIx payload, that has shown early clinical activity with a differentiated and tolerable safety profile.

Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Biohaven Ltd (NYSE: BHVN) dropped $2.21, or about 14.73%, on September 10, 2026 after the Company disclosed that the FDA placed a partial clinical hold on new-patient enrollment in the Company's BHV-7000/opakalim epilepsy trials.